VSTM NASDAQ
Verastem, Inc.
1W: -9.3%
1M: -29.6%
3M: -28.0%
YTD: -40.9%
1Y: -46.8%
3Y: -15.3%
5Y: -87.9%
$4.24
-0.03 (-0.70%)
Weekly Expected Move ±10.5%
$3
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (29)
Cancer Stocks That Are Advancing the Future of Oncology Care
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Verastem (VSTM) Q1 2026 Earnings Transcript
Verastem outlines cash runway into the first half of 2027 while targeting LGSOC self-sustainability in the second half of 2026
Verastem (VSTM) Reports Q1 Loss, Misses Revenue Estimates
SG Americas Securities LLC Purchases 378,958 Shares of Verastem, Inc. $VSTM
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
Verastem (VSTM) Q4 2025 Earnings Call Transcript
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Earnings Summary: Verastem Q4
Verastem GAAP EPS of -$0.50 beats by $0.02, revenue of $17.54M beats by $0.7M
Here are the major earnings after the close Wednesday
Earnings Scheduled For March 4, 2026
Verastem Q4 2025 Earnings Preview
Earnings Outlook For Verastem
Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag
Earnings week ahead: AVGO, CRWD, PLUG, COST, TGT, MRVL, JD, KR, and more
What Makes Verastem (VSTM) a New Buy Stock
Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference